Clik here to view.
Strategic Patient Adherence Awards: “And the Winners Are”
Pharm Exec was proud to partner this year with CBI on the eighth annual Forum on Patient Compliance, Adherence & Persistency. One of the highlights of the event is the presentation of the Strategic...
View ArticleClik here to view.
Lilly Osteoporosis Drug Canned in Phase III Trials
Image by go elsewhere… via Flickr Lilly, on Wednesday, announced that it would not seek regulatory approval for its osteoporosis treatment arzoxifene, because the drug failed to meet certain end...
View ArticleClik here to view.
NICE Stats Spur Controversy and Back Patting
The UK’s National Health Service has released its first statistics that show how NICE approval has affected medicines uptake in the UK. The NHS Information Centre’s Metrics Working Group looked at 26...
View ArticleClik here to view.
Q&A with Steven Paul: Lilly’s New Development Plan
Steven Paul, Lilly Last week, Lilly announced a major restructuring plan focused around the creation of one Developmental Center of Excellence and several individual business units. The media (Pharm...
View ArticleClik here to view.
Judge Spikes Myriad Genetic’s Control of Genes
Image via Wikipedia Score one for nature. A US district court judge on Monday declared that pharma companies can’t patent individual genes because they are they are not, in fact, creating them. Last...
View ArticleClik here to view.
Advisory Panel Rejects Avastin For Breast Cancer Treatment
An FDA advisory panel on Tuesday voted 12–1 to discontinue Avastin (bevacizumab) as a treatment for advanced breast cancer due to post-market studies stating that the treatment does not to increase...
View ArticlePatients on the Picket Line
Good science can’t be rushed, even when the lives of patients hang in the balance. But regulatory science, and its relationship to a drug’s commercial success or failure, can inadvertently block access...
View Article